Vaccinex
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1997-01-01
- Employees
- 40
- Market Cap
- $9M
- Website
- http://www.vaccinex.com
- Introduction
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05102721
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04815720
- Locations
- 🇺🇸
Highlands Oncology Group, PA - North Hills, Springdale, Arkansas, United States
🇺🇸California Cancer Associates for Research and Excellence (CCARE)-Fresno, Fresno, California, United States
🇺🇸UCSF Medical Center at Mission Bay, San Francisco, California, United States
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04381468
- Locations
- 🇺🇸
Pacific Research Network, Inc, San Diego, California, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇺🇸Brain Matters Research, Stuart, Florida, United States
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03268057
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Fayetteville, Arkansas, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Vaccinex Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT02481674
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- Next